Zydus Lifesciences Limited has informed the Exchange about press release dated 25-Apr-2022 titled Zydus announces publication of ���DREAM-ND��� and ���DREAM-D��� Phase 3 trials of Desidustat in ���American Journal of Nephrology���
Press Release Apr 25 2022
Filed with NSE · · 4 pages · English
Summary by 6ix AI
The trials, DREAM-ND and DREAM-D, focus on the treatment of anemia in Chronic Kidney Disease patients using Desidustat, a novel HIF-PH inhibitor. The results indicate that Desidustat met primary and secondary endpoints and was well-tolerated in both non-dialysis and dialysis-dependent patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 18 2022
- Press Release Apr 13 2022
- Press Release Apr 01 2022
- Press Release Mar 21 2022
- Press Release Mar 14 2022
Later from Zydus Lifesciences
- Press Release Apr 26 2022
- Press Release May 03 2022
- Press Release May 06 2022
- Press Release May 13 2022
- Press Release May 26 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences